Evidence map›Paper›PMID 41843553›Full record

ArticlePloS one2026

Estimation of Respiratory Syncytial Virus-attributable hospitalizations among older adults in Japan between 2015 and 2018: An administrative health claims database analysis.

Masafumi Seki, Yasuhiro Kobayashi, Estelle Méroc, Takahiro Kitano, Aleksandra Polkowska-Kramek, Asuka Yoshida, Shuhei Ito, Caihua Liang, Robin Bruyndonckx, Solomon Molalign Moges and 4 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masafumi SekiDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka, Japan.
Yasuhiro KobayashiPfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0003-3587-6611
Estelle MérocP95 Clinical and Epidemiology Services, Leuven, Belgium.
Takahiro KitanoPfizer Japan Inc., Tokyo, Japan.
Aleksandra Polkowska-KramekP95 Clinical and Epidemiology Services, Leuven, Belgium.ORCID https://orcid.org/0000-0003-0148-7183
Asuka YoshidaPfizer Japan Inc., Tokyo, Japan.
Shuhei ItoPfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0003-0289-7766
Caihua LiangPfizer Inc., New York, United States of America.ORCID https://orcid.org/0009-0004-8375-631X
Robin BruyndonckxP95 Clinical and Epidemiology Services, Leuven, Belgium.
Solomon Molalign MogesP95 Clinical and Epidemiology Services, Leuven, Belgium.
Eduardo Conde-SousaP95 Clinical and Epidemiology Services, Leuven, Belgium.
Charles NuttensPfizer Inc., Paris, France.
Bradford D GessnerPfizer Inc., New York, United States of America.
Elizabeth BegierPfizer Inc., Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We estimated the incidence rates (IRs) of respiratory syncytial virus (RSV)-related hospitalizations among adults aged ≥60 years in Japan from 2015 to 2018, using a time-series model-based approach to better understand the disease burden. We obtained hospitalization data from the Medical Data Vision (MDV) database, restricted to Diagnosis Procedure Combination (DPC) hospitals. We estimated the annual age-specific RSV-attributable IR of hospitalizations for five cardiorespiratory outcomes based on selected ICD-10 codes employing a quasi-Poisson regression model. We projected our results to all DPC hospitals in Japan and also to all Japanese hospitals. In adults aged ≥60 years, the annual IR of RSV-attributable cardiorespiratory hospitalizations at DPC hospitals was estimated at between 100 and 124 per 100,000 person-years, projecting to 134-229 cardiorespiratory hospitalizations per 100,000 person-years at all hospitals. For respiratory hospitalizations at DPC hospitals, the annual IR was from 69 to 85 per 100,000 person-years (projecting to 96-157 hospitalizations per 100,000 person-years at all hospitals). IRs for all outcomes were consistently higher among adults aged ≥80 years than those 60-79 years. Our results indicate a high burden of RSV-attributable hospitalizations in older adults in Japan, highlighting the need to implement effective RSV prevention strategies.

Indexed as

HospitalizationRespiratory Syncytial Virus InfectionsAgedAged, 80 and overDatabases, FactualFemaleHumansIncidenceJapanMaleMiddle Aged

Identifiers

PMID41843553
PMCPMC12994811

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.